-
Sector Analysis
Age-Related Macular Degeneration Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2034
The table below presents the key metrics for age-related macular degeneration (AMD) in the seven major pharmaceutical markets (7MM) covered in this report—the US, 5EU (France, Germany, Italy, Spain, and the UK), and Japan—during the forecast period from 2024–34. In 2024, GlobalData estimated the total AMD market to be valued at $7.8 billion across the 7MM, with the US accounting for 67.2% of the market. The five major European markets (5EU) (France, Germany, Italy, Spain, and UK) accounted for 28.9%...
-
Sector Analysis
Age-Related Macular Degeneration: 68-Market Analysis and Sales Forecast tp 2034
This report covers the 68 geographical markets and provides an Excel-based forecast model for the Age-Related Macular Degeneration (AMD) market. Across the 68 markets, sales in the AMD market were $8.9 billion in 2024, growing to $24.1 billion in 2034. The seven major markets (US, France, Germany, Italy, Spain, UK, and Japan) represent approximately 87.0% and 85.2% in 68-market sales in 2024 and 2034, respectively.
-
Product Insights
Dry (Atrophic) Macular Degeneration: Global Clinical Trials Review, 2025
GlobalData's clinical trial report, “Dry (Atrophic) Macular Degeneration - Global Clinical Trials Review, 2025" provides an overview of Dry (Atrophic) Macular Degeneration Clinical trials scenario. This report provides top line data relating to the clinical trials on Dry (Atrophic) Macular Degeneration. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and...
-
Sector Analysis
Age-Related Macular Degeneration Epidemiology Analysis and Forecast to 2034
Age-related macular degeneration (AMD) is a chronic, progressive ophthalmological condition characterized by the gradual degeneration of the macula, the specialized area of the retina responsible for high-acuity central vision. It is recognized as the predominant cause of significant and irreversible vision loss among the older demographic. AMD is clinically staged as early, intermediate, and late. Late AMD, representing the advanced phase of the disease, is further subcategorized into late dry AMD (geographic atrophy) and wet AMD (neovascular AMD) (National Eye...
-
Thematic Analysis
Digital Marketing Trends in Age-related Macular Degeneration
Digital Marketing Trends in Age-related Macular Degeneration Report Overview Genentech’s Vabysmo.com achieved the highest total traffic across branded age-related macular degeneration (AMD) patient sites in the US, with over two million visits from June 2023 to May 2024. This was followed by Bayer’s Eylea.us. Overall, the highest proportion of traffic to branded AMD websites originated from direct sources followed by organic. No traffic was detected in the five major European markets (5EU: France, Germany, Italy, Spain, the UK, and Canada)...
-
Product Insights
Dry (Atrophic) Macular Degeneration - Drugs In Development, 2024
Empower your strategies with our Dry (Atrophic) Macular Degeneration – Drugs In Development, 2024 report and make more profitable business decisions. Dry (atrophic) macular degeneration is a common eye disorder affecting the macula, the central part of the retina responsible for sharp, central vision. It's characterized by the gradual deterioration of light-sensitive cells in the macula. Symptoms include blurred central vision, difficulty seeing fine details, and in later stages, the presence of drusen (yellow deposits) in the retina. Dry AMD typically...
-
Product Insights
Geographic Atrophy - Drugs In Development, 2024
Empower your strategies with our Geographic Atrophy – Drugs In Development, 2024 report and make more profitable business decisions. Geographic atrophy (GA) is an advanced form of age-related macular degeneration (AMD), a progressive eye condition affecting the macula, the central part of the retina responsible for detailed central vision. GA specifically refers to a severe and advanced stage of dry AMD. GA is characterized by the gradual degeneration and death of cells in the macula, leading to the formation of sharply...
-
Product Insights
Wet (Neovascular/Exudative) Macular Degeneration Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
Wet Macular Degeneration Clinical Trial Report Overview A total of 853 wet macular degeneration clinical trials were conducted as of April 2024. The wet macular degeneration clinical trial report provides a comprehensive understanding of the wet macular degeneration clinical trial scenario across regions, and countries (G7 & E7), along with insights into the various phases, trial status, and end points status. The report also includes information about the sponsor type and the prominent sponsors associated with the trials. Key Regions...
-
Product Insights
Age Related Macular Degeneration Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Age-Related Macular Degeneration Clinical Trials Market Report Overview There were a total of 1458 age-related macular degeneration clinical trials conducted as of July 2023. The age-related macular degeneration clinical trial market research report provides a comprehensive overview of the market across regions and countries (G7 & E7). It also provides insights into the various phases, trial status, and end points status. The report includes information about the sponsor types and the prominent sponsors associated with the trials as well. Age-Related...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.